DUX4 and facioscapulohumeral muscular dystrophy: Rashnonejad et al. proposed that DUX4 silencing is the most direct route to Facioscapulohumeral muscular dystrophy (FSHD) therapy and they developed an AAV6-CRISPR-Cas13b strategy to silence DUX4 mRNA.